Scientific KnowledgeUpdated Oct 9, 2026Looking for development status?Clinical stage, comparable drugs/devices, and estimated availability are tracked in the Therapy Pipeline.
Rincell-1
Otic neural progenitor cell therapy
Evidence level
No primary evidence catalogued yet
How it works
A cell therapy (Rinri Therapeutics) using lab-grown otic neural progenitor cells to regenerate damaged auditory neurons, addressing the primary cochlear-nerve degeneration central to the Cochlear Synaptopathy hypothesis. Its first-in-human trial (not yet started; registry start date now Sep 2027) targets neural hearing loss (presbycusis, auditory neuropathy) in cochlear-implant candidates, not tinnitus directly, so any tinnitus benefit remains hypothetical.
This describes the treatment concept as reported in the cited research: a scientific mechanism, not a guarantee of clinical availability.
Explore connections· click any item to explore
Sponsor1
Targets1